Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 312 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurologic Deficits Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

NCT02712996
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke

NCT02243020
View directory record Official record
Conditions
Stroke, Upper Limb Deficits
Interventions
Vagus Nerve Stimulation (VNS)
Device
Lead sponsor
MicroTransponder Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting Phase 4 Interventional

Medication Treatment of ADHD in Pediatric Epilepsy

NCT07594652
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Balance Control in Children With Cerebral Palsy

NCT02456376
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Sensory Integration Testing, SR stimulation & Sensory integration testing
Procedure
Lead sponsor
Temple University
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

NCT01114737
View directory record Official record
Conditions
Phenylketonuria
Interventions
Sapropterin dihydrochloride, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
8 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 5, 2026, 5:25 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2

NCT07321327
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit for Caregivers, Positive Behavioral Management Toolkit for Teachers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

A SMART Design to Improve Sleep Disturbance in Adolescents With Neurodevelopmental Disorders

NCT03730194
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Sleep Disturbance
Interventions
Melatonin, Bedtime Bank
Dietary Supplement · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718910
View directory record Official record
Conditions
DDX3X, Mental Retardation, X-linked 102, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Retrospective Review of Management of Infective Endocarditis

NCT00579761
View directory record Official record
Conditions
Endocarditis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational

Assessment of Attentional Functioning in Children With HIV-1 Infection

NCT00001497
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, HIV Infections, Paralysis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 5:25 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Multiple Concussions in Retired NHL Players

NCT02746523
View directory record Official record
Conditions
Cognitive Deficits, Proprioceptive Disorders
Interventions
Sensory Organization Test, Biomarkers, Conners' Adult ADHD Rating Scale (CAARS), Depression Scale, Cognitive Assessment
Other · Genetic
Lead sponsor
New York Institute of Technology
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 5, 2026, 5:25 PM EDT
Terminated Not applicable Interventional Results available

Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors

NCT01749800
View directory record Official record
Conditions
TBI, Attention Deficits, Motor Impairments
Interventions
GVS, Sham GVS, Armeo Spring
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

NCT00857220
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Carson, California + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting Not applicable Interventional

Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors

NCT05582551
View directory record Official record
Conditions
Childhood Cancer
Interventions
Highlighting Patients at Risk for Sensory Screening (HPARSS)
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting No phase listed Observational

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718936
View directory record Official record
Conditions
ADNP, Helsmoortel-Van Der Aa Syndrome, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
2 Years and older
Enrollment
30 participants
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 5, 2026, 5:25 PM EDT
Withdrawn Not applicable Interventional

Attention Intervention Management

NCT01779427
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Attention Deficit Hyperactivity Disorder (ADHD), Head Injury, Brain Concussion, Head Injuries, Closed
Interventions
AIM
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 5, 2026, 5:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder

NCT01452061
View directory record Official record
Conditions
Autism Spectrum Disorder, Attention Deficit/Hyperactivity Disorder, Developmental Delay
Interventions
Not listed
Lead sponsor
Thomas W. Frazier, Ph.D
Other
Eligibility
1 Year to 12 Years
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 5, 2026, 5:25 PM EDT
Completed Phase 1Phase 2 Interventional

My Scrivener® - Measuring Effectiveness and Dose Response in Children

NCT00919906
View directory record Official record
Conditions
Asperger's Syndrome, Dyslexia, Cerebral Palsy, Attention Deficit Disorder, ADHD, Traumatic Brain Injury, Stroke
Interventions
My Scrivener(R)
Device
Lead sponsor
Obslap Research LLC
Industry
Eligibility
5 Years to 19 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Sep 5, 2026, 5:25 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Repeated Operational Stress and Limited Recovery on Resilience Capacity

NCT06784544
View directory record Official record
Conditions
Sleep, Inadequate, Energy Deficit, Iron Absorption, High Physical Activity
Interventions
Operational Stressors
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
17 Years to 39 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 5, 2026, 5:25 PM EDT
Recruiting Not applicable Interventional

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

NCT05661084
View directory record Official record
Conditions
Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
Interventions
Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 5, 2026, 5:25 PM EDT